These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 34411603)

  • 61. Alzheimer's disease and gastrointestinal microbiota; impact of
    Doulberis M; Kotronis G; Gialamprinou D; Polyzos SA; Papaefthymiou A; Katsinelos P; Kountouras J
    Int J Neurosci; 2021 Mar; 131(3):289-301. PubMed ID: 32125206
    [No Abstract]   [Full Text] [Related]  

  • 62. Retinoic Acid and the Gut Microbiota in Alzheimer's Disease: Fighting Back-to-Back?
    Endres K
    Curr Alzheimer Res; 2019; 16(5):405-417. PubMed ID: 30907321
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hydrogen Sulfide Ameliorates Homocysteine-Induced Alzheimer's Disease-Like Pathology, Blood-Brain Barrier Disruption, and Synaptic Disorder.
    Kamat PK; Kyles P; Kalani A; Tyagi N
    Mol Neurobiol; 2016 May; 53(4):2451-2467. PubMed ID: 26019015
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Mannan oligosaccharide attenuates cognitive and behavioral disorders in the 5xFAD Alzheimer's disease mouse model via regulating the gut microbiota-brain axis.
    Liu Q; Xi Y; Wang Q; Liu J; Li P; Meng X; Liu K; Chen W; Liu X; Liu Z
    Brain Behav Immun; 2021 Jul; 95():330-343. PubMed ID: 33839232
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Gut microbiota and pro/prebiotics in Alzheimer's disease.
    Pluta R; Ułamek-Kozioł M; Januszewski S; Czuczwar SJ
    Aging (Albany NY); 2020 Mar; 12(6):5539-5550. PubMed ID: 32191919
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of oxysterols on the blood-brain barrier: implications for Alzheimer's disease.
    Gosselet F; Saint-Pol J; Fenart L
    Biochem Biophys Res Commun; 2014 Apr; 446(3):687-91. PubMed ID: 24275140
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Microbiota modulation as preventative and therapeutic approach in Alzheimer's disease.
    Bonfili L; Cecarini V; Gogoi O; Gong C; Cuccioloni M; Angeletti M; Rossi G; Eleuteri AM
    FEBS J; 2021 May; 288(9):2836-2855. PubMed ID: 32969566
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota.
    Li B; He Y; Ma J; Huang P; Du J; Cao L; Wang Y; Xiao Q; Tang H; Chen S
    Alzheimers Dement; 2019 Oct; 15(10):1357-1366. PubMed ID: 31434623
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Manipulation of the diet-microbiota-brain axis in Alzheimer's disease.
    Lee D; Lee VM; Hur SK
    Front Neurosci; 2022; 16():1042865. PubMed ID: 36408394
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The dynamic blood-brain barrier.
    Keaney J; Campbell M
    FEBS J; 2015 Nov; 282(21):4067-79. PubMed ID: 26277326
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Drosophila as a Model for Microbiota Studies of Neurodegeneration.
    Kitani-Morii F; Friedland RP; Yoshida H; Mizuno T
    J Alzheimers Dis; 2021; 84(2):479-490. PubMed ID: 34569965
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The role of gut microbiota in pathogenesis of Alzheimer's disease.
    Bostanciklioğlu M
    J Appl Microbiol; 2019 Oct; 127(4):954-967. PubMed ID: 30920075
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Role of Probiotics and Diet in the Management of Neurological Diseases and Mood States: A Review.
    Thangaleela S; Sivamaruthi BS; Kesika P; Chaiyasut C
    Microorganisms; 2022 Nov; 10(11):. PubMed ID: 36422338
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease.
    Biron KE; Dickstein DL; Gopaul R; Jefferies WA
    PLoS One; 2011; 6(8):e23789. PubMed ID: 21909359
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cracking Brain Diseases from Gut Microbes-Mediated Metabolites for Precise Treatment.
    Gong Y; Chen A; Zhang G; Shen Q; Zou L; Li J; Miao YB; Liu W
    Int J Biol Sci; 2023; 19(10):2974-2998. PubMed ID: 37416776
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases.
    Chen X; Ghribi O; Geiger JD
    J Alzheimers Dis; 2010; 20 Suppl 1(Suppl 1):S127-41. PubMed ID: 20164568
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Regulation of gut microbiota in Alzheimer's disease mice by silibinin and silymarin and their pharmacological implications.
    Shen L; Liu L; Li XY; Ji HF
    Appl Microbiol Biotechnol; 2019 Sep; 103(17):7141-7149. PubMed ID: 31236617
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Anti-high mobility group box-1 monoclonal antibody protects the blood-brain barrier from ischemia-induced disruption in rats.
    Zhang J; Takahashi HK; Liu K; Wake H; Liu R; Maruo T; Date I; Yoshino T; Ohtsuka A; Mori S; Nishibori M
    Stroke; 2011 May; 42(5):1420-8. PubMed ID: 21474801
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Human Gut Microbiota in Health and Alzheimer's Disease.
    Szablewski L
    J Alzheimers Dis; 2018; 62(2):549-560. PubMed ID: 29480188
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Microbiota Alterations in Alzheimer's Disease: Involvement of the Kynurenine Pathway and Inflammation.
    Garcez ML; Jacobs KR; Guillemin GJ
    Neurotox Res; 2019 Aug; 36(2):424-436. PubMed ID: 31089885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.